TPO and rheumatoid arthritis: Rituximab, a B-cell-depleting anti-CD20 monoclonal antibody, belimumab, an inhibitor of B-cell activating factor (BAFF), and eltrombopag, an oral TPO-RA, have each demonstrated clinical benefit in small observational studies [4,7].